Evaluating the risk of osteoporosis-related adverse events with proton pump inhibitors: a pharmacovigilance study
BackgroundProton pump inhibitors (PPIs) are the most effective antacids and are widely used in the treatment of acid-related diseases. However, the impact of PPIs on bone remains controversial. This study aimed to explore the association between PPIs and osteoporosis-related adverse events in the re...
Saved in:
Main Authors: | Jingkai Di, Nan Yang, Yicong Zhao, Shuai Chen, Zijian Guo, Dongdong He, Chuan Xiang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-07-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1582908/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
An in-depth investigation of NAs-induced osteoporosis adverse events: a real-world, network toxicology and molecular docking analysis
by: Jingkai Di, et al.
Published: (2025-07-01) -
Sex differences in drug-induced osteoporosis: a pharmacovigilance study based on the FAERS database
by: Lu Liu, et al.
Published: (2025-07-01) -
Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Qi Song, et al.
Published: (2025-06-01) -
METHOTREXATE AND PROTON PUMP INHIBITORS: ARE THERE ANY NEGATIVE PHARMACOLOGIAL EFFECTS?
by: Andrey E Karateev, et al.
Published: (2014-02-01) -
Pharmacovigilance and signal detection of adverse drug events associated with proteasome inhibitors in multiple myeloma: a real-world analysis using the FAERS database
by: JunYun Luo, et al.
Published: (2025-12-01)